Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)
If you experience any of the following symptoms, contact your provider immediately: Severe abdominal pain Persistent vomiting or diarrhea Inability to tolerate fluids Heart palpitations Sudden fatigue or dizziness Side Effects: What's Normal vs
Role of RP11-83J16.1, a Novel Long non-Coding RNA, in Rheumatoid Arthritis
My diabetes was diagnosed in 2016, when GLP-1 injectables werent widely available, only tablets were
Gut microbiotabrain connection The gut microbiota consists of over 10 trillion diverse microbes, increasing in density distally through the GI tract 238
